




## Supplementary Figures




**Figure S1. Expression landscape of CD276 (B7-H3) in NSCLC.** (A) B7-H3 expression was markedly upregulated in NSCLC tumors compared to normal lung tissues. (B) Expression levels demonstrated a positive correlation with disease stage, showing a significant increase from stage II to stage I. (C) A significant association was found between gender and B7-H3 expression, suggesting it may be a relevant factor in disease biology.



**Figure S2. Detection of B7-H3 expression.** (A) Flow cytometric analysis of B7-H3 surface expression in NSCLC cells lines. (B) B7-H3 expression was verified by Western blotting.




**Figure S3. Migration of luteolin-treated NSCLC cells assessed by wound-healing assay.** Representative images of A549 and HCC827 cell migration are shown (scale bar=200 μm). \*\*\*\*P < 0.0001.




**Figure S4. Expression and binding analysis of B7-H3/CD16 bispecific antibody. (A)** Purified B7-H3/CD16 bispecific antibody. **(B)** Binding capacity of the B7-H3/CD16 bispecific antibody to B7-H3 and CD16 antigen, respectively.

A



B



**Figure S5. Effects of LY294002 and luteolin on NSCLC cells. (A)** Colony formation of NSCLC cells treated with either LY294002 or luteolin alone or in combination. **(B)** The migration of NSCLC cells with either LY294002 or luteolin alone or in combination. (scale bar=100  $\mu$ m). The concentrations of LY294002 and luteolin are 10 nM, respectively. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , and \*\*\*\* $P < 0.0001$ .